eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (136 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-06-02. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastaticrandomizationsmallsurgeryagents
  Phrases that lowered it: subjectsallergicclinicalrelevantparticipation in
• Sponsor's past termination rate: 21.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past trials: 260 (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 20 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: supportive care (lowers risk) · Design
• Drug's FAERS reports with a death: 13.1% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 92.7% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 43937 (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? NCT03269994 · started 2017 · scored riskier than 22% of active trials completed
• A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula NCT03174353 · started 2018 · scored riskier than 87% of active trials completed
• Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection NCT02160808 · started 2014 · scored riskier than 96% of active trials completed
• Prevention of Postoperative Pancreatic Fistula by Somatostatin NCT03000946 · started 2017 · scored riskier than 68% of active trials completed
• Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer NCT02767752 · started 2016 · scored riskier than 88% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.